Shares of Advaxis, Inc. (NASDAQ:ADXS) were down 11.8% during trading on Tuesday after Cantor Fitzgerald lowered their price target on the stock from $19.00 to $5.00. Cantor Fitzgerald currently has an overweight rating on the stock. Advaxis traded as low as $1.75 and last traded at $1.95. Approximately 4,035,195 shares were traded during mid-day trading, an increase of 227% from the average daily volume of 1,232,556 shares. The stock had previously closed at $2.21.

Other analysts have also recently issued research reports about the stock. HC Wainwright set a $23.00 price objective on shares of Advaxis and gave the company a “buy” rating in a research note on Wednesday, December 27th. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

How to Become a New Pot Stock Millionaire

Several hedge funds and other institutional investors have recently made changes to their positions in ADXS. Wells Fargo & Company MN lifted its stake in shares of Advaxis by 2.6% in the second quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock valued at $290,000 after purchasing an additional 1,144 shares during the period. TIAA CREF Investment Management LLC lifted its stake in shares of Advaxis by 2.4% in the second quarter. TIAA CREF Investment Management LLC now owns 98,164 shares of the biotechnology company’s stock valued at $637,000 after purchasing an additional 2,329 shares during the period. Northern Trust Corp lifted its stake in shares of Advaxis by 4.4% in the second quarter. Northern Trust Corp now owns 456,817 shares of the biotechnology company’s stock valued at $2,965,000 after purchasing an additional 19,434 shares during the period. Vanguard Group Inc. lifted its stake in shares of Advaxis by 7.2% in the second quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock valued at $11,572,000 after purchasing an additional 119,980 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Advaxis in the second quarter valued at about $352,000. Hedge funds and other institutional investors own 29.79% of the company’s stock.

The firm has a market cap of $81.84, a P/E ratio of -0.83 and a beta of 1.06.

Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. The firm had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million. Advaxis had a negative net margin of 940.64% and a negative return on equity of 131.78%. sell-side analysts predict that Advaxis, Inc. will post -2.36 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Advaxis (ADXS) Trading Down 11.8% Following Analyst Downgrade” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/03/14/advaxis-adxs-trading-down-11-8-following-analyst-downgrade.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.